The Great Bifurcation: AI Suppliers Surge While Spenders Suffer

Market Regime

A narrow, two-speed market. Only 32.8% of stocks advanced on July 23, the S&P 500 is flat over the past month, and the average stock is down -0.87% on the day. Yet this isn't a crash — the VIX has collapsed to 17.05 from 18.65 a week ago, sticky CPI continues to fall (2.81%, from 3.09%), the yield curve remains positively steep at +36 bps, and unemployment dropped to 4.2%. The macro backdrop is Goldilocks, but the internal dispersion is ferocious. The market is rotating, not retreating: 1,166 stocks remain in confirmed uptrends, averaging +6.65% over the past month, while 820 downtrenders average -2.17%.

Mega Forces

1. The AI Infrastructure Supercycle Is Now Unmistakable. GOOGL raised its 2026 capex guide to $195–205B (up from $180–190B) and signaled further increases into 2027. AMD announced a $5B investment in Anthropic with a 2 GW chip commitment. Intel reported its fastest revenue growth in 15 years (+25%), with Data Center and AI revenue up 59%. The hyperscaler buildout is accelerating, not peaking.

2. Energy Has Become the Stealth AI Trade. WTI crude at $84+ is surging on its own merits (OPEC+ discipline, geopolitical risk), but the data center buildout adds a structural demand layer. Energy is the best-performing US sector over 1 month (+9.5%), with Oil & Gas Downstream themes up +32% and refining names like PBF gaining +52%. Every new data center needs power — and right now, that means natural gas and oil.

3. The Great Rotation: From Growth Spenders to Value Earners. The market is punishing companies that spend on AI (GOOGL -7.1% on the day after raising capex, RSI 31) while rewarding those who supply the infrastructure or profit from it. Healthcare earnings beats (MEDP +14.7%, NVCR +28%, NVEC +55%) and energy cash flows are drawing capital that fled technology and semis.

What's Working

Healthcare — especially CROs and biotech. Clinical Research Organizations (CROs) returned +21.9% over 1 month with +6.3% on July 23 alone. MEDP surged 14.7% on a record bookings beat, reversing Q1 malaise. Metabolic & Endocrine Disorders (+23% 1M) and Rare & Orphan Diseases (+20%) continue to benefit from the post-ATTR-CM de-risking rotation into biotech. The regulatory and M&A backdrop remains supportive — Eli Lilly's $2.8B ATAI acquisition and Vertex's $10B CRNX deal signal that Big Pharma is paying up for pipeline.

Energy — all parts of the chain. From E&P to refining to oilfield services, energy is firing on all cylinders. The ETF leaderboard is an oil refinery convention: CRAK +21.5% 1M, UGA +19.8%, USO +16.9%. Oceaneering (OII) beat Q2 estimates by 40% and raised EBITDA guidance. This has legs — the WTI rally has further room given low spare capacity and rising geopolitical premiums.

Defense & Industrials. Lockheed Martin gained +10.5% on the day, Oracle secured a $7B DoD contract, and the long-cycle defense buildout is providing earnings visibility that consumer-facing industrials lack.

What's Not Working

Semiconductors — especially memory and specialty. Memory Chips -26%, Specialty Semiconductor Technologies -24%, Power Semiconductors -25.6%. The South Korea (-22.2% 1M) and Taiwan (-8.8%) selloffs reflect this. Even positive catalysts (Amkor's NVDA partnership, Intel's blowout earnings) fail to hold — stocks are being sold into strength. This is a valuation reset, not a fundamentals collapse, but it may take several more weeks to wash out.

Quantum and Advanced Batteries. Quantum Computing -33%, Advanced Battery Cell Technology -33%, Lithium Mining -28%. These are liquidity-sensitive, high-duration stories getting crushed as capital rotates to cash-flow-heavy energy and healthcare names.

Consumer Discretionary. TMUS fell -10.8% despite beating Q2 profit estimates and raising FCF guidance — the market is punishing "good but not great" results. Consumer Staples (+1.4% 1M) is defensive but unexciting, while Discretionary (-0.8%) drifts.

Strategy

The defining tension of this market: AI spending is exploding, but the market is selling the spenders and buying the beneficiaries. This suggests a barbell approach:

• Energy infrastructure — the direct physical beneficiary of data center buildout (power, cooling, equipment). Oil refining and natural gas exposure remain underappreciated as AI plays.
• Healthcare — the rotation destination with the most room to run. CROs and biotech with near-term catalysts (data readouts, regulatory decisions) offer asymmetric upside in a low-breadth market.
• Be selective on AI spenders — GOOGL at RSI 31 is getting oversold, but the narrative of "capex that depresses FCF" may persist until the next earnings cycle proves ROI. The AI enablers (optical, packaging, networking) are more interesting at these pullbacks than the hyperscalers themselves.

The VIX at 17 and positive yield curve argue against being defensive. But with only one-third of stocks advancing, this is a stock-picker's market, not a beta rally. Stay in uptrends (1,166 names) and avoid catching falling knives in semi-land — even the good news is getting sold.